Concepedia

Charles W. Bruseo

CW

Statistics

Publications

10

Citations

783

H-Index

10

Active since

1995

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Tris Pharma (United States)

Charles W. Bruseo is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1995–2004

10

Publications

10

Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex

Maı̈na Lepourcelet, Ying-Nan P. Chen, Dennis S. France et al. · Cancer Cell · 2004 · 643 citations · Full text

, , +3

Characterization of a Potent and Selective Endothelin-B Receptor Antagonist, IRL 2500

Joseph L. Balwierczak, Charles W. Bruseo, Dominick DelGrande et al. · Journal of Cardiovascular Pharmacology · 1995 · 21 citations

Pharmacological Properties of CGS 35066, a Potent and Selective Endothelin-Converting Enzyme Inhibitor, in Conscious Rats

Angelo J. Trapani, Michael E. Beil, Charles W. Bruseo et al. · Journal of Cardiovascular Pharmacology · 2000 · 20 citations

, , +15

Design and Synthesis of a Potent and Selective Endothelin-Converting Enzyme Inhibitor, CGS 35066

Arco Y. Jeng, Stéphane De Lombaert, Michael E. Beil et al. · Journal of Cardiovascular Pharmacology · 2000 · 20 citations

, , +14

Characterization of a Potent and Selective Endothelin-B Receptor Antagonist, IRL 2500

Joseph L. Balwierczak, Charles W. Bruseo, Dominick DelGrande et al. · Journal of Cardiovascular Pharmacology · 1995 · 15 citations

, , +11

1–5 of 10